CS
DMTX

Credit Suisse’s Dimension Therapeutics, Inc DMTX Stock Holding History

Credit Suisse’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-16,488
Closed -$132K – 4383
2016
Q3 		$132K Buy
16,488
+2,332
+16% +$16.9K ﹤0.01% 3888
2016
Q2 		$84K Buy
+14,156
New +$108K ﹤0.01% 4090

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Credit Suisse's DMTX Position: Q4 2016 in Review

Credit Suisse sold out of Dimension Therapeutics, Inc (DMTX) in Q4 2016, closing a stake of 16,488 shares — an estimated $132K sold.

Credit Suisse first reported a position in DMTX in Q2 2016 and held it in 2 quarters. The position peaked at $132K in Q3 2016. 55 funds tracked by Wall St. Rank hold DMTX as of Q4 2016.

  • Credit Suisse reported no remaining Dimension Therapeutics, Inc position as of Q4 2016 after selling out during the quarter.
  • Credit Suisse sold 16,488 Dimension Therapeutics, Inc shares in Q4 2016, an estimated $132K.
  • Credit Suisse first reported a position in Dimension Therapeutics, Inc in Q2 2016 and held it in 2 quarters.
  • Credit Suisse's Dimension Therapeutics, Inc position peaked at $132K in Q3 2016.
  • 55 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.